Related Videos
ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT
Antonio Gioradano, MD, presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progressing on prior CDK4/6 inhibitor - data from phase 2 FOURLIGHT-1 study.
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Research Update for Triple Negative MBC | 2021-2022 EMBRACE MBC Virtual Forum Series
Antonio Giordano, MD, PhD; Sarah Sammons, MD; and Morgan Rutter, MS, BSN, RN, discuss advances in research and treatment for patients with triple negative metastatic breast cancer.
